Why the study?
Does fixed-dose irbesartan/hydrochlorothiazide improve blood pressure control without compromising safety compared to irbesartan monotherapy in patients with severe hypertension?
Does fixed-dose irbesartan/hydrochlorothiazide improve blood pressure control without compromising safety compared to irbesartan monotherapy in patients with severe hypertension?
Initial fixed-dose irbesartan/HCTZ provides more rapid BP lowering with a comparable safety profile to irbesartan monotherapy in patients with severe hypertension.
Answers are grounded in this paper and cite their sources.
Favors initial fixed-dose irbesartan/HCTZ for faster BP control in severe hypertension; extends RCT evidence for combination therapy with comparable safety.
This prospective, double-blind, multicenter trial compared the safety and tolerability of irbesartan/hydrochlorothiazide (HCTZ) fixed-dose combination therapy with irbesartan monotherapy in patients with severe hypertension (seated diastolic blood pressure (SeDBP) >or=110 mm Hg, mean BP 172/113 mm Hg at baseline). Patients were randomized 2:1 to 7 weeks' irbesartan/HCTZ 150/12.5 mg to 300/25 mg (n = 468) or irbesartan 150 mg to 300 mg (n = 227). The incidence of treatment-related adverse events (AEs) was similar with combination and monotherapy (11.3% and 10.1%), and most AEs were mild-to-moderate. The combined incidence of prespecified AEs was lower with irbesartan/HCTZ than with irbesartan (8.8% vs. 11.5%). There were no treatment-related serious AEs or deaths. At week 5, more patients achieved SeDBP < 90 mm Hg compared to irbesartan (47% vs. 33%; P = 0.0005). Despite more rapid and aggressive BP lowering, initial fixed-dose irbesartan/HCTZ demonstrated a comparable AE profile to irbesartan monotherapy in patients with severe hypertension.
No takes yet. Share an insight, caveat, or question.
Neutel et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: